A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2011-07-04
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with
acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).